1-4 of 4
Russell Hull
Close
Sort by
Journal Articles

The Safety and Efficacy of Full Versus Reduced Dose Betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention with Extended Duration Betrixaban (APEX) Trial

Alexander T Cohen, MBBS MSc MD, Rim Halaby, MD, Serge Korjian, MD, Yazan Daaboul, MD, Donald Szlosek, Douglas Arbetter, MPH, Samuel Z. Goldhaber, MD, Russell Hull, MBBS, Adrian Hernandez, MD, Alexander Gold, MD, Brian Wiens, PhD, Robert Harrington, MD, C. Michael Gibson, MD
Journal: Blood
Blood (2016) 128 (22): 3824.
https://doi.org/10.1182/blood.V128.22.3824.3824
Published: 2016
Journal Articles

Rate of Late Venous Thromboembolism Events In High-Risk Medical Patients

Russell Hull, MBBS, MSc, FRCPC, Duane Bates, BScPharm, ACPR, Cynthia Brocklebank, PharmD, ACPR, Nelly Komari, BPharm, MSc, Tazmin Merali, BPharm, MBA
Journal: Blood
Blood (2010) 116 (21): 82.
https://doi.org/10.1182/blood.V116.21.82.82
Published: 2010
Journal Articles

Rivaroxaban Compared with Enoxaparin for the Prevention of Venous Thromboembolism In Acutely Ill Medical Patients: MAGELLAN Study Methodology

Alexander Thomas Cohen, Theodore Erich Spiro, Harry Roger Bùˆller, Lloyd Haskell, Da-Yi Hu, Russell Hull, Alexandre Mebazaa, Geno Merli, Sebastian Schellong, Alexander Spyropoulos, Victor Tapson
Journal: Blood
Blood (2010) 116 (21): 3331.
https://doi.org/10.1182/blood.V116.21.3331.3331
Published: 2010
Journal Articles

Non-Pathogenic Anti-Heparin/PF4 Antibodies Generated by Low Molecular Weight Heparins Mediate Procoagulant Effects.

Jeanine M. Walenga, PhD, Debra Hoppensteadt, PhD, Evangelos Litinas, MD, Harry L. Messmore, Jr, MD, Bruce E Lewis, MD, Gundu Rao, PhD, Russell Hull, MD, Jawed Fareed, PhD
Journal: Blood
Blood (2010) 116 (21): 1091.
https://doi.org/10.1182/blood.V116.21.1091.1091
Published: 2010